Trade

with

TG Therapeutics Inc
(NASDAQ: TGTX)
AdChoices
10.89
+0.84
+8.36%
After Hours :
10.99
+0.10
+0.92%

Open

10.06

Previous Close

10.05

Volume (Avg)

370.36k (422.39k)

Day's Range

10.06-10.91

52Wk Range

2.97-12.45

Market Cap.

415.13M

Dividend Rate ( Yield )

-

Beta

1.97

Shares Outstanding

38.12M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 152.38k

    • Net Income

    • -20.48M

    • Market Cap.

    • 415.13M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -19,525.88

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.97

    • Forward P/E

    • -6.85

    • Price/Sales

    • 2,000.00

    • Price/Book Value

    • 7.97

    • Price/Cash flow

    • -16.89

      • EBITDA

      • -19.52M

      • Return on Capital %

      • -80.24

      • Return on Equity %

      • -95.41

      • Return on Assets %

      • -80.24

      • Book Value/Share

      • 1.37

      • Shares Outstanding

      • 38.12M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 23.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -1.59

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -19,525.88

            • 39.38

            • Net Profit Margin

            • -19,525.88

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 18.91

              • 2.92

              • Quick Ratio

              • 17.31

              • 2.35

              • Interest Coverage

              • -30.57

              • 38.02

              • Leverage Ratio

              • 1.08

              • 2.21

              • Book Value/Share

              • 1.37

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -10.20

                • 217.39

                • P/E Ratio 5-Year High

                • -284.34

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.97

                • 124.82

                • Price/Sales Ratio

                • 2,000.00

                • 9.52

                • Price/Book Value

                • 7.39

                • 8.61

                • Price/Cash Flow Ratio

                • -16.89

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -95.41

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -80.24

                        (-99.60)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -87.88

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.00

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -22.97M
                      Operating Margin
                      -15,071.43
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -16.89
                      Ownership

                      Institutional Ownership

                      84.10%

                      Top 10 Institutions

                      71.49%

                      Mutual Fund Ownership

                      16.16%

                      Float

                      62.41%

                      5% / Insider Ownership

                      42.80%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • JPM Global Healthcare

                      •  

                        2,032,927

                      • 0.00

                      • 5.33

                      • Candriam Eqs L Biotechnology

                      •  

                        500,000

                      • 0.00

                      • 1.31

                      • Prudential Jennison Health Sciences

                      •  

                        404,922

                      • 0.00

                      • 1.06

                      • Vanguard Total Stock Mkt Idx

                      •  

                        395,789

                      • 6.68

                      • 1.04

                      • Vanguard Extended Market Index Fund

                      •  

                        364,570

                      • 0.00

                      • 0.96

                      • iShares Russell 2000 (AU)

                      •  

                        355,638

                      • -1.46

                      • 0.88

                      • iShares Russell 2000 Growth

                      •  

                        167,932

                      • 0.34

                      • 0.41

                      • TFS Market Neutral Fund

                      •  

                        123,796

                      • -25.86

                      • 0.32

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • LFB Biotechnologies SA S U

                      •  

                        7,500,000

                      • +50.00%

                      • 20.01

                      • Opus Point Partners, LLC

                      •  

                        4,524,560

                      • 0.00%

                      • 12.07

                      • Bridger Management LLC

                      •  

                        2,547,000

                      • 0.00%

                      • 6.68

                      • J P Morgan Asset Management (UK) Ltd

                      •  

                        2,273,776

                      • -19.51%

                      • 5.96

                      • Baker Bros Advisors LLC

                      •  

                        2,160,965

                      • 0.00%

                      • 5.67

                      • Vanguard Group, Inc.

                      •  

                        769,030

                      • +4.92%

                      • 2.02

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treat...morement of cancer and other underserved therapeutic needs. Currently, the Company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes in...morevolved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy’s Laboratories’, among others.lessless

                      Key People

                      Michael S. Weiss

                      CEO/Chairman of the Board/Director/President

                      Mr. Sean A. Power

                      CFO/Chief Accounting Officer/Secretary/Treasurer

                      Neil Herskowitz

                      Director

                      Mr. Laurence N. Charney

                      Director

                      Dr. William J. Kennedy, PhD

                      Director

                      • TG Therapeutics Inc

                      • 3 Columbus Circle

                      • New York, NY 10019

                      • USA.Map

                      • Phone: +1 212 554-4484

                      • Fax: +1 212 554-4531

                      • tgtherapeutics.com

                      Incorporated

                      1993

                      Employees

                      14

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: